Eli Lilly's drug "triple-G" shows high effectiveness in the fight against obesity. Eli Lilly has launched six early clinical programs and 34 discovery programs targeting incretins, amylins and novel targets. Key assets include the obesity and weight loss drugs tirsepatide and orforglipron. Orforglipron, tablet form, has shown a 12.4% reduction in body weight in clinical trials. Eli Lilly expects to launch it in the US in the second quarter after FDA approval. In 2024, demand for Mounjaro and Zepbound drugs exceeded supply, leading to a $55 billion investment in 13 manufacturing facilities. More than 75% of new drugs are outside of incretins and amylins, targeting diseases such as high lipoprotein(a), chronic pain, or early Alzheimer's disease.[1][2][3]